Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (2): 249-252.doi: 10.3969/j.issn.1673-8225.2011.02.014

Previous Articles     Next Articles

Effects of serum containing Jinwugutong capsule substances on secretion of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in osteoblasts 

Liu Chun-ying1, Zheng Wen-kui2, Zu Jin-chi2, Zhou Yu-juan1, Liu Xin-xia1, Liu Li1, Zhang Zhe1   

  1. 1Department of Pharmacology, Hebei University Health Science Center, Baoding  071000, Hebei Province, China
    2Deartment of Orthopaedics, Affiliated Hospital of Hebei University, Baoding  071000, Hebei Province, China
  • Received:2010-07-09 Revised:2010-09-27 Online:2011-01-08 Published:2011-01-08
  • About author:Liu Chun-ying★, Master, Lecturer, Department of Pharmacology, Hebei University Health Science Center, Baoding 071000, Hebei Province, China liuchy310@163.com
  • Supported by:

    the Science Research Item of Administration of Traditional Chinese Medicine in Hebei Province, No. 2009149

PDF

379

Abstract:

BACKGROUND: Jinwugutong capsule (JWGTC) has the evident therapeutic effect on postmenopausal osteoporosis, but the specific mechanism is unclear.
OBJECTIVE: To investigate the effects of serum containing JWGTC on expression of osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) in osteoblasts.
METHODS: Osteoporosis model was made in ovariotomy method. JWGTC was intragastric administrated into ovariectomized rats. The 3rd passage of osteoblast was harvested from 24-hour SD rats and cultured by normal serum, ovariectomized serum and JWGTC treated serum, respectively for 72 hours. ELASA method was used to detect the mRNA expression of osteoprotegerin and RANKL.
RESULTS AND CONCLUSION: Compared with the normal serum group, expression of osteoprotegerin in osteoblasts of the ovariectomized serum group decreased significantly (P < 0.01), while the RANKL expression increased remarkably (P < 0.05); compared with the ovariectomized serum group, expression of osteoprotegerin in osteoblasts of the JWGTC treated serum was increased (P < 0.05), while the expression of RANKL decreased (P < 0.05). JWGTC can prevent and treat osteoporosis by increasing the expression of osteoprotegerin and inhibiting the mRNA expression of RANKL.

CLC Number: